Adagio Medical (ADGM) announced the completion of enrollment of the FULCRUM-VT FDA investigational device exemption study evaluating the company’s vCLAS Cryoablation System for ablation of monomorphic ventricular tachycardia. The vCLAS System, which has been granted breakthrough device designation by the FDA, is built on the company’s proprietary ultra-low temperature cryoablation technology platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADGM: